ARDX
$5.83
Ardelyx, Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritabl...
Recent News
Ardelyx Touts IBSRELA’s 73% Growth, Reaffirms $1B 2029 Goal and Details CIC Phase III Plan
Ardelyx (NASDAQ:ARDX) executives outlined commercial momentum for IBSRELA and XPHOZAH, key investment priorities for 2026, and development plans for a chronic idiopathic constipation (CIC) expansion at a Global Healthcare Conference, highlighting what management characterized as improving execution
Assessing Ardelyx (ARDX) Valuation After Recent Share Price Weakness
What Ardelyx’s Recent Trading Performance Tells You Ardelyx (ARDX) has been under pressure recently, with the share price declining about 16% over the past month, even as the past 3 months show a gain of roughly 6%. Over a longer horizon, the stock’s total return is about 18% over the past year and very large over the past 3 years, while the 5 year total return reflects an overall decline. See our latest analysis for Ardelyx. With the share price at about $6.17, Ardelyx’s recent 30 day share...
Is Ardelyx (ARDX) Pricing In Its Potential After Recent Share Price Weakness
If you are wondering whether Ardelyx at US$6.19 is pricing in its full potential or trading at a discount, you are in the right place to assess what the current market price really reflects. The stock has seen a 4.3% decline over the last 7 days and a 15.4% decline over the last 30 days. It shows a 0.7% return year to date and a 66.0% return over 3 years, which gives important context before judging today’s valuation. Recent coverage around Ardelyx has focused on its position in the...
Ardelyx CEO Sells 41k Shares as Company Announces Huge Partnership
Ardelyx is coming off a strong Q4 earnings report for fiscal year 2025. But how is the stock performing?
Ardelyx (ARDX) Valuation Check After 2025 Results And Strong 2026 Growth Guidance
Ardelyx (ARDX) is back in focus after its full year 2025 report showed revenue of US$407.32 million and a net loss of US$61.6 million, along with new 2026 revenue guidance. See our latest analysis for Ardelyx. The recent guidance and product updates have arrived after a sharp pullback, with a 7 day share price return of a 16.3% decline and a 30 day share price return of a 26% decline. Ardelyx still shows a 12.1% one year total shareholder return and a very large three year total shareholder...